Medulloblastoma clinical trials

The registry lists 317 studies for Medulloblastoma across more than 10 countries. 51 are recruiting or about to start. 92 of them are mainly about Medulloblastoma (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-09.

Get an email when these change. Save the Medulloblastoma studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 170
Recruiting: 36
Terminated: 32
Active, not recruiting: 31
Status unknown: 18
Withdrawn: 13

Phase

Phase 1: 148
Phase 2: 111
Phase 3: 16
Early Phase 1: 9
Phase 4: 2

Where

United States: 245
Canada: 42
Australia: 28
Puerto Rico: 24
France: 19
Switzerland: 15

Who runs them

National Cancer Institute (NCI) (53) · Children's Oncology Group (19) · Pediatric Brain Tumor Consortium (16) · St. Jude Children's Research Hospital (12) · Giselle Sholler (7) · Novartis Pharmaceuticals (7) · National Institutes of Health Clinical Center (CC) (6) · Memorial Sloan Kettering Cancer Center (6)

What is being tested here

Drugs under test in Medulloblastoma studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Etoposide	3	1	16
Cyclophosphamide	3	0	14
Temozolomide	2	1	22
Cisplatin	2	3	11
Lutetium Lu 177 dotatate	2	0	2
Carboplatin	1	2	20
Irinotecan	1	0	9
Vincristine	1	0	8
Topotecan	1	0	7
Methotrexate	1	1	6

Drug classes tested here Alkylating agents 5 open · Tyrosine kinase inhibitors (TKIs) 2 open · Antimetabolites 2 open · Antimitotic agents 1 open · PARP inhibitors 1 open

Coming up

4phase 3 studies under way

17studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Dec 2026International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma · Phase 3 · Universitätsklinikum Hamburg-Eppendorf
Nov 2027Effect of Metformin on Behaviour and the Brain in Children Treated for a Brain Tumour · Phase 3 · Donald Mabbott
Dec 2026Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors · Valent Technologies, LLC
Dec 2026Medulloblastoma Online Video-based Exercise Pilot Study · Aron Onerup
Dec 2026Clinical Study of Allogeneic Vγ9Vδ2 T Cells in the Treatment of Brain Malignant Glioma · Beijing Tiantan Hospital
Jan 2027Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma · City of Hope Medical Center
Feb 2027Digoxin Medulloblastoma Study · H. Lee Moffitt Cancer Center and Research Institute
Mar 2027Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms · Jazz Pharmaceuticals
May 2027Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors · Seattle Children's Hospital
May 2027Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors · Sun Yat-sen University

Who these studies take

Of the 36 Medulloblastoma studies recruiting now, 4 (11%) set no upper age limit and 30 (83%) stop at 75 or younger. 33 (92%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (3%) take healthy volunteers.

Recruiting studies that take each age, of 36
Age	Women	Men
10	31 (86%)	31 (86%)
18	33 (92%)	33 (92%)
30	16 (44%)	16 (44%)
40	7 (19%)	7 (19%)
50	7 (19%)	7 (19%)
65	6 (17%)	6 (17%)
75	6 (17%)	6 (17%)
85	6 (17%)	6 (17%)

Across all 317 studies, recruiting or not: 75% stop at 75 or younger and 72% at 65; 83% take children; 0% are for women only and <1% for men only; 3% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Medulloblastoma studies take

Of 46 phase 1 interventional studies under Medulloblastoma, half reached primary completion within 65 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 1	65 mo44–92 · 46 studies	—	65 mo44–88 · 41 studies
Phase 2	66 mo51–92 · 42 studies	—	68 mo52–114 · 38 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 13, 2026.

Results posted1

Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have SurgeryOct 19, 2026NCT03904862

Studies

Recruiting first, then most recently updated. Showing 50 of 317. Browse all 317 → or search them.